Efficacy and safety of ixekizumab over 4Â years of open-label treatment in a phase 2 study in chronic plaque psoriasis

Article ID	Journal	Published Year	Pages	File Type
8714896	Journal of the American Academy of Dermatology	2018	39 Pages	PDF

Abstract

Efficacy was shown to be maintained for up to 4Â years of ixekizumab treatment.

Keywords

sPGA NAPSI DLQI MACE VAS LOCF SAE PSSI RCT randomized placebo-controlled trial OLE IBD BCC PSA TEAE psoriatic arthritis static Physician Global Assessment standard deviation interleukin interleukin 17 Ixekizumab PASI Inflammatory bowel disease major adverse cardiovascular event treatment emergent adverse event Psoriasis Area Severity Index Nail Psoriasis Severity Index Dermatology Life Quality Index Long-term Serious adverse event Open-label last observation carried forward visual analog scale Hospital Anxiety and Depression Scale HADS Psoriasis Basal cell carcinoma

Related Topics

Health Sciences Medicine and Dentistry Dermatology

Efficacy and safety of ixekizumab over 4Â years of open-label treatment in a phase 2 study in chronic plaque psoriasis

Authors

Claus MD, DMSci, Kenneth MD, Alexandra B. MD, Mark MD, Andrew MD, Craig MD, Daniel MD, PhD, Missy MS, Russel PhD, Gregory PhD,